Off-Label Drug Use To Receive CMS Scrutiny, McClellan Says
This article was originally published in The Pink Sheet Daily
The Centers for Medicare & Medicaid Services plans to improve its collaborations with outside experts to better understand Rx drug use among seniors. The agency will share the information with providers.
You may also be interested in...
Policy decision for covering unapproved, non-compendial indications for cancer drugs is still pending, but will not mean a "sea change" in reimbursement, agency official says. Real issue is "unorganized" approach to off-label use as a whole in the U.S.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.